BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 1828259)

  • 1. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
    De Ruysscher D; Sobis H; Vandeputte M; Waer M
    J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of asialo-GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific cytotoxic T cells.
    Varkila K
    Clin Exp Immunol; 1987 Sep; 69(3):652-9. PubMed ID: 3499271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A subpopulation of asialo GM1-positive cells plays a protective role in the occurrence of graft-versus-host disease (GVHD) in mice.
    De Ruysscher D; Sobis H; Vandeputte M; Waer M
    Transplant Proc; 1991 Feb; 23(1 Pt 1):804. PubMed ID: 1824997
    [No Abstract]   [Full Text] [Related]  

  • 4. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of radiation field and fractionation schedule of total lymphoid irradiation (TLI) on the induction of suppressor cells and stable chimerism after bone marrow transplantation in mice.
    Waer M; Ang KK; Van der Schueren E; Vandeputte M
    J Immunol; 1984 Feb; 132(2):985-90. PubMed ID: 6228603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation in mice after total lymphoid irradiation: influence of breeding conditions and strain of recipient mice.
    Waer M; Ang KK; Van der Schueren E; Vandeputte M
    J Immunol; 1984 Feb; 132(2):991-6. PubMed ID: 6228604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1.
    Charley MR; Mikhael A; Bennett M; Gilliam JN; Sontheimer RD
    J Immunol; 1983 Nov; 131(5):2101-3. PubMed ID: 6355291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T; Sato S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
    Wang SB; Guo KY; Hu DM; Yin B
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia.
    OKunewick JP; Kociban DL; Machen LL; Buffo MJ
    Bone Marrow Transplant; 1995 Sep; 16(3):451-6. PubMed ID: 8535319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.